Literature DB >> 32617835

Anti-Sporothrix activity of ibuprofen combined with antifungal.

Luana Pereira Borba-Santos1, Marcio Nucci2, Antonio Ferreira-Pereira3, Sonia Rozental4.   

Abstract

The in vitro activity of ibuprofen, a nonsteroidal anti-inflammatory drug, was evaluated against Sporothrix brasiliensis and S. schenckii, either alone or in combination with amphotericin B, itraconazole, or terbinafine. The inhibitory activity of ibuprofen as a single agent was determined according to minimum inhibitory concentration (MIC) values, while the effect of ibuprofen combined with amphotericin B, itraconazole, or terbinafine was estimated by microdilution checkerboard methodology. The ultrastructural alterations of S. schenckii after exposure to the combination of ibuprofen and amphotericin B were evaluated by scanning electron microscopy (SEM) and flow cytometry analysis. As a single agent, ibuprofen inhibited Sporothrix growth with a MIC median of 256 μg/mL, while the MIC medians of ibuprofen in combination with antifungals were 16 μg/mL and 128 μg/mL. The MIC values of amphotericin B, itraconazole, and terbinafine were reduced when isolates were co-incubated with ibuprofen, mainly the polyene. The major alteration after treatment with the ibuprofen/amphotericin B combination was the increase in the presence of filamentous forms and high membrane damage with loss of plasma membrane integrity. In summary, we demonstrated that ibuprofen increases the in vitro activity of antifungals, mainly amphotericin B, against S. brasiliensis and S. schenckii. Future in vivo studies exploring combination therapy with ibuprofen and antifungals in animal models are needed to confirm its efficacy.

Entities:  

Keywords:  Amphotericin B; Ibuprofen; Sporothrix brasiliensis; Sporothrix schenckii

Year:  2020        PMID: 32617835      PMCID: PMC7966684          DOI: 10.1007/s42770-020-00327-9

Source DB:  PubMed          Journal:  Braz J Microbiol        ISSN: 1517-8382            Impact factor:   2.476


  16 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

2.  Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.

Authors:  Adepemi O Ogundeji; Carolina H Pohl; Olihile M Sebolai
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?

Authors:  Aspasia Katragkou; Emmanuel Roilides; Thomas J Walsh
Journal:  Expert Opin Pharmacother       Date:  2016-06       Impact factor: 3.889

4.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

5.  Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species.

Authors:  Cidália Pina-Vaz; Filipe Sansonetty; Acácio G Rodrigues; J Martinez-DE-Oliveira; António F Fonseca; Per-Anders Mårdh
Journal:  J Med Microbiol       Date:  2000-09       Impact factor: 2.472

6.  [Hospitalizations and deaths related to sporotrichosis in Brazil (1992-2015)].

Authors:  Eduardo Mastrangelo Marinho Falcão; José Berilo de Lima Filho; Dayse Pereira Campos; Antonio Carlos Francesconi do Valle; Francisco Inácio Bastos; Maria Clara Gutierrez-Galhardo; Dayvison Francis Saraiva Freitas
Journal:  Cad Saude Publica       Date:  2019-05-02       Impact factor: 1.632

7.  Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.

Authors:  J Król; U Nawrot; M Bartoszewicz
Journal:  J Mycol Med       Date:  2018-03-28       Impact factor: 2.391

8.  Sporotrichosis in Rio de Janeiro, Brazil: Sporothrix brasiliensis is associated with atypical clinical presentations.

Authors:  Rodrigo Almeida-Paes; Manoel Marques Evangelista de Oliveira; Dayvison Francis Saraiva Freitas; Antônio Carlos Francesconi do Valle; Rosely Maria Zancopé-Oliveira; Maria Clara Gutierrez-Galhardo
Journal:  PLoS Negl Trop Dis       Date:  2014-09-18

Review 9.  Sporothrix Species Causing Outbreaks in Animals and Humans Driven by Animal-Animal Transmission.

Authors:  Anderson Messias Rodrigues; G Sybren de Hoog; Zoilo Pires de Camargo
Journal:  PLoS Pathog       Date:  2016-07-14       Impact factor: 6.823

10.  Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics.

Authors:  Rosane Orofino-Costa; Priscila Marques de Macedo; Anderson Messias Rodrigues; Andréa Reis Bernardes-Engemann
Journal:  An Bras Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.896

View more
  3 in total

1.  Special issue on sporotrichosis: challenges to deal with the new emerging pathogenic species.

Authors:  Leila M Lopes-Bezerra; Sandro Rogério de Almeida
Journal:  Braz J Microbiol       Date:  2021-02-18       Impact factor: 2.476

Review 2.  Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends.

Authors:  Anderson Messias Rodrigues; Sarah Santos Gonçalves; Jamile Ambrósio de Carvalho; Luana P Borba-Santos; Sonia Rozental; Zoilo Pires de Camargo
Journal:  J Fungi (Basel)       Date:  2022-07-26

Review 3.  Drug repurposing strategies in the development of potential antifungal agents.

Authors:  Qian Zhang; Fangyan Liu; Meng Zeng; Yingyu Mao; Zhangyong Song
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-21       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.